0001022079-26-000040
SEC filingQuest Diagnostics reported Q1 2026 revenues of $2.90 billion, up 9.2% year-over-year, raised full-year revenue and EPS guidance, reflecting strong organic growth and operational execution.
Quest Diagnostics delivered robust Q1 2026 results with net revenues of $2.90 billion, a 9.2% increase from $2.652 billion in Q1 2025, driven primarily by 9.0% organic growth and 10.9% requisition volume growth despite a 1.3% decline in revenue per requisition. Diagnostic Information Services revenues rose 9.4% to $2.832 billion. GAAP operating income improved 15.5% to $399 million (13.8% margin vs. 13.0%), while adjusted operating income grew 10.0% to $447 million (15.4% margin). Reported diluted EPS increased 15.5% to $2.24, and adjusted EPS rose 13.1% to $2.50. CEO Jim Davis attributed the performance to disciplined execution, including innovative diagnostics like Quest AD-Detect for Alzheimer’s and growth in cardiometabolic testing, alongside expansions in consumer channels via questhealth.com and Co-Lab Solutions with Corewell Health. Operational highlights include the AI Companion tool's 350,000 engagements and Project Nova planning. The company raised full-year 2026 guidance, lifting revenue outlook to $11.78-$11.90 billion (6.8%-7.8% growth) from $11.70-$11.82 billion, reported EPS to $9.58-$9.78 from $9.45-$9.65, and adjusted EPS to $10.63-$10.83 from $10.50-$10.70, signaling confidence in sustained momentum. Balance sheet remains solid with $393 million in cash, though operating cash flow dipped to $278 million amid working capital changes.